Hepatitis B virus infection among first-time blood donors in Italy: Prevalence and correlates between serological patterns and occult infection

Blood Transfusion

Volumn 11, Issue 2, 2013, Pages 281-288

  Romanò, Luisa ^a   Velati, Claudio ^b   Cambiè, Giuseppe ^c   Fomiatti, Laura ^d   Galli, Claudio ^e   Zanetti, Alessandro Remo ^a  

^a UNIVERSITY OF MILAN   (Italy)

^b MAGGIORE HOSPITAL   (Italy)

^c Hospital of Lodi   (Italy)

^d Transfusion Medicine and Haematology Department   (Italy)

^e ABBOTT DIAGNOSTICS   (Italy)

Author keywords

Anti HBc; Blood screening; HBV; HBV DNA; Occult infection

Indexed keywords

HEPATITIS B SURFACE ANTIGEN; VIRUS DNA;

ARTICLE; BLOOD DONOR; BLOOD TRANSFUSION; CONTROLLED STUDY; FEMALE; HEPATITIS B; HUMAN; ITALY; MAJOR CLINICAL STUDY; MALE; SEROPREVALENCE;

ADULT; BLOOD; BLOOD DONORS; BLOOD SAFETY; DNA, VIRAL; FEMALE; HEPATITIS B; HEPATITIS B CORE ANTIGENS; HEPATITIS B SURFACE ANTIGENS; HEPATITIS B VIRUS; HUMANS; ITALY; MALE; MIDDLE AGED;

EID: 84876893188     PISSN: 17232007     EISSN: None     Source Type: Journal    
DOI: 10.2450/2012.0160-12     Document Type: Article

References (46)

1. Hoofnagle JH, Seefe LB, Bales ZB, et al. Type B hepatitis after transfusion with blood containing antibody to hepatitis B core antigen. N Engl J Med 1978;298:1379-83. (Pubitemid 8358627)
2. Lai CL, Ratziu V, Yuen MF, et al. Viral hepatitis B. Lancet 2003;362:2089-94. (Pubitemid 38032767)
3. Candotti D, Allain JP. Transfusion-transmitted hepatitis B virus infection. J Hepatol 2009;51:798-809.
4. Allain JP, Candotti D. Diagnostic algorithm for HBV safe transfusion. Blood Transf 2009;7:174-82.
5. Decreto del Ministero della Salute 3 marzo 2005. Protocolli per l'accertamento della idoneità del donatore di sangue e di emocomponenti. Gazzetta Ufficiale n. 85, 13 Aprile 2005.
6. Decreto Ministero della Salute 27 marzo 2008. Modificazioni all'allegato 7 del decreto 3 marzo 2005 in materia di esami obbligatori ad ogni donazione di sangue e controlli periodici. Gazzetta Ufficiale n. 117, 20 Maggio 2008.
7. Kuhns M, Busch MP. New strategies for blood donor screening for hepatitis B virus: nucleic acid testing versus immunoassay methods. Mol Diagn Ther 2006;10:77-91.
8. Nubling CM, Heiden M, Chudy M, et al. Experience of mandatory nucleic acid test (NAT) screening across all blood organizations in Germany: NAT yield versus breakthrough transmissions. Transfusion 2009;49:1850-8.
9. Velati C, Romanò L, Fomiatti L, et al. Impact of nucleic acid testing for hepatitis B virus, hepatitis C virus, and human immunodeficiency virus on the safety of blood supply in Italy: a 6-year survey. Transfusion 2008;48:2205-13.
10. Kleinman SH, Kuhns MC, Todd DS, et al. Frequency of HBV DNA detection in US blood donors testing positive for the presence of anti-HBc: implications for transfusion transmission and donor screening. Transfusion 2003;43:696-704. (Pubitemid 36629113)
11. Yoshikawa A, Gotanda Y, Minegishi K, et al. Lengths of hepatitis B viremia and antigenemia in blood donors: preliminary evidence of occult (hepatitis B surface antigen-negative) infection in the acute stage. Transfusion 2007;47:1162-71. (Pubitemid 46934305)
12. Gonzàlez R, Torres P, Castro E, et al. Efficacy of hepatitis B virus (HBV) DNA screening and characterization of acute and occult HBV infections among blood donors from Madrid, Spain. Transfusion 2010;50:221-30.
13. Raimondo G, Allain JP, Brunetto MR, et al. Statements from the Taormina expert meeting on occult hepatitis B virus infection. J Hepatol 2008;49:652-7.
14. Allain JP, Hewitt PE, Tedder RS, Williamson LM for the anti-HBc screening study group. Evidence that anti-HBc but not HBV DNA testing may prevent some HBV transmission by transfusion. Br J Haematol 1999;107:186-95. (Pubitemid 29500825)
15. Roth WK, Weber M, Petersen D, et al. NAT for HBV and anti-HBc testing increase blood safety. Transfusion 2002;42:869-75
16. Schmidt M, Nubling CM, Scheiblauer H, et al. Anti-HBc screening of blood donors: a comparison of nine anti-HBc tests. Vox Sang 2006;91:237-43. (Pubitemid 44337281)
17. Thomas HIJ. Relative functional affinity of specific anti-core IgG in different cathegories of hepatitis B virus infection. J Med Virol 1997;51:189-97. (Pubitemid 27157799)
18. Rodella A, Galli C, Terlenghi L, et al. Quantitative analysis of HBsAg, IgM anti-HBc and anti-HBc avidity in acute and chronic hepatitis B. J Clin Virol 2006;37:206-12. (Pubitemid 44559777)
19. Mosley JW, Stevens CE, Aach RD, et al. Donor screening for antibody to hepatitis B core antigen and hepatitis B virus infection in transfusion recipients. Transfusion 1995;35:5-12.
20. Ascione A, Forte GB, Amitrano L, et al. Serological markers of hepatitis B virus infection in healthy volunteer blood donors in Campania (Southern Italy). Vox Sang 1981;41:146-50. (Pubitemid 11056145)
21. Giusti G, Gaeta GB, Russo M, Bedarida G. HBsAg carriers among blood donors in Italy - a multicentre study in 107 blood banks. Infection 1989;17:237-9. (Pubitemid 19207989)
22. Zuccaro O, Tosti ME, Mele A, Spada E, and the SEIEVA collaborative group. Epidemiology of acute viral hepatitis in Italy: results of the surveillance through SEIEVA. Rapp ISTISAN 2012;4:1-24.
23. Hennig H, Puchta I, Luhm J, et al. Frequency and load of hepatitis B virus DNA in first-time blood donors with antibodies to hepatitis B core antigen. Blood 2002;100:2637-41.
24. Gutiérrez C, Devesa M, Loureiro CL. Molecular and serological evaluation of surface antigen negative hepatitis B virus infection in blood donors from Venezuela. J Med Virol 2004;73:200-7. (Pubitemid 38542673)
25. Manzini P, Girotto M, Borsotti R, et al. Italian blood donors with anti-HBc and occult hepatitis B virus infection. Haematologica 2007;92:1664-70. (Pubitemid 350248246)
26. Allain JP, Cox L. Challenges in hepatitis B detection among blood donors. Curr Opin Hematol 2011;18:461-6.
27. Zheng X, Ye X, Zhang L, et al. Characterization of occult hepatitis B virus infection from blood donors in China. J Clin Microbiol 2011;49:1730-7.
28. Pondè RAA, Cardoso DDP, Ferro MO. The underlying mechanisms for the "anti-HBc alone" serological profile. Arch Virol 2010;155:149-58.
29. Inaba S, Ito A, Miyata Y, et al. Individual nucleic amplification technology does not prevent all hepatitis B virus transmission by blood transfusion. Transfusion 2006;46:2028-9. (Pubitemid 44631612)
30. Satake M, Taira R, Yugi H, et al. Infectivity of blood components with low hepatitis B virus DNA levels identified in a lookback program. Transfusion 2007;47:1197-205. (Pubitemid 46934327)
31. Stramer SL, Krysztof DE, Brodsky JP. Sensitivity comparison of two Food and Drug Administration-licensed, triplex nucleic acid test automated assays for hepatitis B virus DNA detection and associated projections of United States yield. Transfusion 2011;51:2012-22.
32. Manzini P, Abate ML, Valpreda C, et al. Evidence of acute primary occult hepatitis B virus infection in an Italian repeat blood donor. Transfusion 2009;49:757-64.
33. Dettori S, Candido A, Kondili LA, et al. Identification of low HBV-DNA levels by nucleic acid amplification test (NAT) in blood donors. J Infect 2009;59:128-33.
34. Iudicone P, Miceli M, Palange M, et al. Hepatitis B virus blood screening: impact of nucleic amplification technology testing implementation on identifying hepatitis B surface antigen non-reactive window period and chronic infections. Vox Sang 2009;96:292-7.
35. Stramer SL, Zou S, Notari EP, et al. Blood donation screening for hepatitis B virus markers in the era of nucleic acid testing: are all tests of value? Transfusion 2012;52:440-6.
36. Roth WK, Busch MP, Schuller A et al. International survey on NAT testing of blood donations: expanding implementation and yield from 1999 to 2009. Vox Sang 2012;102:82-90.
37. Niederhauser C, Weingand T, Candotti D, et al. Fatal outcome of a hepatitis B virus transfusion-transmitted infection. Vox Sang 2010;98:504-7.
38. Vermeulen M, Dickens C, Lelie N, et al. Hepatitis B virus transmission by blood transfusion during 4 years of individualdonation nucleic acid testing in South Africa: estimated and observed window period risk. Transfusion 2012;52:880-92.
39. Vermeulen M, Lelie N, Sykes W, et al. Impact of individual-donation nucleic acid testing on risk of human immunodeficiency virus, hepatitis B virus, and hepatitis C virus transmission by blood transfusion in South Africa. Transfusion 2009;49:1115-25.
40. Pondè RAA. The underlying mechanisms for the "isolated positivity for the hepatitis B surface antigen (HBsAg) " serological profile. Med Microbiol Immunol 2011;200:13-22.
41. ® assay for the detection of hepatitis B virus surface antigen (HBsAg). J Clin Virol 2011;51:59-63.
42. El Chaar M, Candotti D, Crowther RA, Allain JP. Impact of hepatitis B virus surface protein mutations on the diagnosis of occult hepatitis B virus infection. Hepatology 2010;52:1600-10.
43. Wu C, Zhang X, Tian Y, et al. Biological significance of amino acid substitutions in hepatitis B surface antigen (HBsAg) for glycosylation, secretion, antigenicity and immunogenicity of HBsAg and hepatitis B virus replication. J Gen Virol 2010;91:483-92.
44. Bremer CM, Saniewski M, Wend UC, et al. Transient occult hepatitis B virus infection in a blood donor with high viremia. Transfusion 2009;49:1621-9.
45. Foy MC, Thio CL, Hwang HS, et al. False-negative hepatitis B virus (HBV) surface antigen in a vaccinated dialysis patient with a high level of HBV DNA in the United States. Clin Vacc Immunol 2012;19:820-22.
46. Velati C, Fomiatti L, Baruffi L, et al. Criteria for hepatitis B virus screening and validation of blood components in Italy: the position of the SIMTI HBV working group. Blood Transfus 2011;9:455-61.